Martin Shkreli Appears at House Hearing on Drug Pricing, Refuses to Answer Questions
Pharmaceutical chief Martin Shkreli has arrived at a hearing where U.S. lawmakers want to hear from about severe hikes for a drug sold by a company that he acquired.But it’s unlikely the former CEO of Turing Pharmaceuticals will answer questions in his appearance Thursday before the House Oversight and Government Reform Committee.
Shkreli, widely scorned for hiking the price of a long-established and potentially lifesaving drug by more than 5,000 percent, has said he’s exercising his Fifth Amendment right against self-incrimination. The 32-year-old Shkreli faces separate criminal charges of securities fraud related to another drug company. Also going before lawmakers is the interim CEO of Canada’s largest drugmaker, Valeant Pharmaceuticals. Both companies have sharply raised prices for drugs taken by patients with heart problems, AIDS, cancer and other conditions.